~~<i id='F7AF5BB027'><strike id='F7AF5BB027'><tt id='F7AF5BB027'><pre id='F7AF5BB027'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：leisure time 2025-09-27 23:03:41 - browse：13413

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Health AI: on the border between health care and tech

focus

knowledge

hotspot

entertainment

focus

AdobeAsBristolMyersSquibbworkstobuilditstreatmentforaheartconditionthatcancausedifficultybreathingin

WSS

Will General Catalyst be the first of many hospital takeovers?

Idaho college killings prosecutors challenge defense's grand jury claims

Sanofi CEO defends move to abandon profit guidance, boost research

Free speech concerns arise in wake of journal editor Eisen's firing

Extreme heat events are a public health emergency

Dozens dead from Maui wildfires: What we know about the victims

focus

comprehensive

focus

What does generative AI mean for health care? We asked experts

What to know about the judge who will handle the Trump case

Hollywood unions extend contract negotiations for actors

Novo Nordisk touts Wegovy study, but still struggling with supply

After affirmative action ruling, medical educators look to 'holistic review'

10 million people disenrolled from Medicaid over past six months

Wildfire smoke exposes gaps in outdoor worker protections

BMS, looking to build heart drug business, turns to AI for diagnosis

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Megan Rapinoe shares emotional post following US Women's World Cup exit

knowledge

Will General Catalyst be the first of many hospital takeovers?

Removing probiotics from the NICU could threaten preemies' health

Removing probiotics from the NICU could threaten preemies' health

Judge sides with young activists in first

Megan Rapinoe shares emotional post following US Women's World Cup exit

Novo Nordisk touts Wegovy study, but still struggling with supply

knowledge

hotspot

entertainment

focus